Santarus reiterated at outperform by RBC

RBC Capital Markets analyst Douglas Miehm reiterated Santarus Inc. at outperform, speculative risk, and an $8 price target on news that Zegerid prescriptions were up 6.4% for the week, according to IMS data. While back-to-back weeks with growth above 6% are an improvement, Miehm said he would like to see continued growth in this range for the next few weeks to decide the effects of the company's formulary wins. Shares of the San Diego-based pharmaceutical company were up 5 cents, or 0.68%, at $7.36. (Nasdaq: SNTS)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.